Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph+) CML/ALL patients.

Devon M Greer; Susanne Liewer; Mojtaba Akhtari

doi:10.1200/jco.2014.32.15_suppl.e18021

Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph+) CML/ALL patients.

Devon M Greer, Susanne Liewer, Mojtaba Akhtari

Medicine

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	32
DOIs	https://doi.org/10.1200/jco.2014.32.15_suppl.e18021
State	Published - May 20 2014

Disciplines

Oncology
Pathology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1200/jco.2014.32.15_suppl.e18021License: Unspecified

OpenUrl availability

Full text

Cite this

@article{96ac49b595044bafba748add0cdefdfe,

title = "Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph+) CML/ALL patients.",

author = "Greer, {Devon M} and Susanne Liewer and Mojtaba Akhtari",

note = "e18021 Background: Ponatinib is a tyrosine kinase inhibitor (TKI) indicated for the treatment of Ph+ chronic myeloid leukemia (CML) or acute lymphocytic leukemia (ALL) in the absence of other appropriate TKI therapies or presence of the T315I BCR-ABL mutation. Hematologic toxicity can result in dose reductions, interruptions and discontinuation of drug therapy.",

year = "2014",

month = may,

day = "20",

doi = "10.1200/jco.2014.32.15_suppl.e18021",

language = "American English",

volume = "32",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph+) CML/ALL patients.

AU - Greer, Devon M

AU - Liewer, Susanne

AU - Akhtari, Mojtaba

N1 - e18021 Background: Ponatinib is a tyrosine kinase inhibitor (TKI) indicated for the treatment of Ph+ chronic myeloid leukemia (CML) or acute lymphocytic leukemia (ALL) in the absence of other appropriate TKI therapies or presence of the T315I BCR-ABL mutation. Hematologic toxicity can result in dose reductions, interruptions and discontinuation of drug therapy.

PY - 2014/5/20

Y1 - 2014/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.e18021

U2 - 10.1200/jco.2014.32.15_suppl.e18021

DO - 10.1200/jco.2014.32.15_suppl.e18021

M3 - Article

VL - 32

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph+) CML/ALL patients.

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this